Design, Synthesis and Antiviral Evaluation of Pyrido[1,2-

Wenlong Xu, Wu Ni, Ziyan Zhou, Zhenhui Ju, Sisi Liu, Shixiang Pan, Xiangrui Jiang

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenlong XuSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.

Wu NiCollege of Chemistry, Huazhong Agricultural University, Wuhan 430070, China.

Ziyan ZhouShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.

Zhenhui JuShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.

Sisi LiuCollege of Chemistry, Huazhong Agricultural University, Wuhan 430070, China.ORCID 0000-0002-6814-134X

Shixiang PanShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.ORCID 0000-0002-1320-5852

Xiangrui JiangShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.

Funding

Chinese Academy of Sciences XDA0530201Department of Science and Technology of Shandong Province 2024CXPT029Shanghai Institute of Materia Medica SIMM0120231003

6 · The paper itself

Abstract

Porcine epidemic diarrhea virus (PEDV) is the pathogen responsible for porcine epidemic diarrhea, causing significant economic losses to the swine industry. During the replication of PEDV, the genome mutates rapidly, making the effectiveness of commercial vaccines uncertain when facing newly emerging prevalent variants. More importantly, there are currently no safe and effective specific antiviral drugs available.

Indexed as

Antiviral AgentsDrug DesignPorcine epidemic diarrhea virusPyrimidinonesAnimalsMicrosomes, LiverMolecular StructureStructure-Activity RelationshipSwineVirus ReplicationAntiviral AgentsPyrimidinonesantiviralPEDVpyrido[1,2-c]pyrimidin-1-one (PPO) derivativesSAR

Identifiers

PMID42123850

DOI10.3390/molecules31091480

PMCPMC13165446

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.